Stay updated with breaking news from Sarepta. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Outside advisers to the Food and Drug Administration on Friday voted in favor of granting accelerated approval to Sarepta Therapeutics' gene therapy to treat Duchenne muscular dystrophy. The... | May 12, 2023
Swiss National Bank lessened its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Rating) by 3.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 190,300 shares of the biotechnology company’s stock after selling 6,800 shares during the quarter. Swiss National Bank […]
Advisers to the U.S. Food and Drug Administration will discuss Sarepta Therapeutics Inc's gene therapy for Duchenne muscular dystrophy at a closely-watched meeting on Friday, days after the agency... | May 12, 2023
WFO SHREVEPORT Warnings, Watches and Advisories for Sunday, May 7, 2023
Adeno-Associated Virus Vectors in Gene Therapy Market